Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis
TORONTO, ONTARIO -- (Marketwired) -- 04/26/16 -- Arch Biopartners Inc. (Arch or the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), a portfolio based biotechnology company, today announced the European Medicines Authority (EMA) Committee for Orphan Medicinal …